Table 1.

Demographic parameters of 8 patients who enrolled in part one the study.

Patient #	Age (years)	Gender identity	Reason for TT	Ethnicity	Testosterone preparation
1	56	Cisgender man	Primary hypogonadism	White	Testosterone gel daily
2	69	Cisgender man	Secondary hypogonadism	White	IM testosterone cypionate weekly
3	37	Cisgender man	Primary hypogonadism due to testicular dysgenesis	Latino/Hispanic	IM testosterone cypionate weekly
4	33	Transgender man	Gender-affirming hormone therapy	White	IM testosterone cypionate weekly
5	21	Transgender man	Gender-affirming hormone therapy	White	IM testosterone cypionate weekly
6	69	Cisgender man	Mixed primary and secondary hypogonadism (mumps orchitis plus obesity and undertreated sleep apnea)	White	Testosterone gel daily
7	31	Cisgender man	Disorder of sexual development (XX male with CAH due to 21-hydroxylase deficiency	Latino/Hispanic	IM testosterone cypionate weekly
8	21	Cisgender man	Congenital hypogonadotropic hypogonadism (Pasqualini syndrome- previously known as fertile eunuch)	White	IM testosterone cypionate weekly

TT, testosterone therapy. CAH, congenital adrenal hyperplasia. IM, intramuscular.